ACST Acasti Pharma Inc.

0.67
-0.02  -3%
Previous Close 0.69
Open 0.68
Price To Book 58.49
Market Cap 58,849,993
Shares 89,207,819
Volume 1,696,533
Short Ratio
Av. Daily Volume 5,122,511
Stock charts supplied by TradingView

NewsSee all news

  1. Neptune Provides Updates on Non-Core Investments

    LAVAL, QC, Jan. 13, 2020 /CNW Telbec/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) (TSX:NEPT), a health and wellness company focused on extraction, purification and

  2. Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving

  3. Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or

  4. Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

    LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  5. Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

    Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ:ACST). The full research publication is available here and available on our website at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due mid-February 2020.
CaPre (TRILOGY 1 and 2)
Hypertriglyceridemia

Latest News

  1. Neptune Provides Updates on Non-Core Investments

    LAVAL, QC, Jan. 13, 2020 /CNW Telbec/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) (TSX:NEPT), a health and wellness company focused on extraction, purification and

  2. Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving

  3. Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

    Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or

  4. Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

    LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  5. Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

    Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ:ACST). The full research publication is available here and available on our website at

  6. Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre's Novel Mechanism of Action in Diabetes

    Data from a new preclinical mouse study suggests a unique mechanism of CaPre compared to metformin and icosapent ethyl (VASCEPA®) in a diet-induced obesity animal model Preliminary, statistically significant findings

  7. Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

    LAVAL, Québec, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  8. Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

    LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  9. Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

    LAVAL, Quebec, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  10. Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®

    LAVAL, Québec, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  11. Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  12. Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

    Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints of interest such as

  13. Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

    LAVAL, Quebec, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company")  (NASDAQ:ACST, TSXV:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its

  14. Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

    LAVAL, Québec, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  15. Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

    LAVAL, Quebec, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of